Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007141322 - G PROTEIN COUPLED RECEPTOR 39 (GPR39)

Publication Number WO/2007/141322
Publication Date 13.12.2007
International Application No. PCT/EP2007/055636
International Filing Date 08.06.2007
IPC
G01N 33/74 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones
G01N 33/564 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
564for pre-existing immune complex or autoimmune disease
CPC
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
12Antihypertensives
G01N 2333/726
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
72for hormones
726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Applicants
  • JANSSEN PHARMACEUTICA N.V. [BE]/[BE] (AllExceptUS)
  • MOREAUX, Benoit Christian Jean-Claude [BE]/[BE] (UsOnly)
  • MOECHARS, Diederik Willem Elisabeth [BE]/[BE] (UsOnly)
  • VER DONCK, Luc August Laurentius [BE]/[BE] (UsOnly)
Inventors
  • MOREAUX, Benoit Christian Jean-Claude
  • MOECHARS, Diederik Willem Elisabeth
  • VER DONCK, Luc August Laurentius
Common Representative
  • JANSSEN PHARMACEUTICA N.V.
Priority Data
06115158.508.06.2006EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) G PROTEIN COUPLED RECEPTOR 39 (GPR39)
(FR) RÉCEPTEUR COUPLÉ À LA PROTÉINE G 39 (GPR39)
Abstract
(EN)
The present invention relates to the functional characterization of the G protein coupled receptor GPR39 and to compounds, which modify or regulate GPR39 protein activity. In particular the present invention relates to methods of screening for agonists or antagonists of GPR39 in order to identify compounds capable of modulating carbohydrate metabolism and to the therapeutic uses of these compounds. In particular to the use of GPR39 in methods to identify compounds that are capable to enhance glucose control in a subject and which are effective for preventing and/or treating pathologies related with an impaired carbohydrate metabolism, in particular in the prevention and/or treatment of diabetes including associated complications thereof, or of the metabolic syndrome including associated complications thereof. Including Type 1 (insulin-dependent or IDDM), Type 2 (non- insulin- dependent diabetes mellitus), maturity-onset diabetes of the young (MODY) and gestational diabetes.
(FR)
La présente invention concerne la caractérisation fonctionnelle du récepteur couplé à la protéine G GPR39 ainsi que des composés qui modifient ou régulent l'activité de la protéine GPR39. En particulier, la présente invention concerne des méthodes de criblage d'agonistes ou antagonistes du GPR39 afin d'identifier des composés capables de moduler le métabolisme des hydrates de carbone, ainsi que les utilisations thérapeutiques de ces composés, en particulier l'utilisation du GPR39 dans des méthodes d'identification de composés qui sont capables d'améliorer la régulation du glucose chez un sujet et qui sont efficaces dans la prévention et/ou le traitement de pathologies liées à une compromission du métabolisme des hydrates de carbone, en particulier dans la prévention et/ou le traitement du diabète, y compris les complications associées à ce dernier, ou du syndrome métabolique, y compris les complications associées à ce dernier, comprenant le diabète de type 1 (insulinodépendant ou DID), le diabète de type 2 (non insulinodépendant ou DNID), le syndrome MODY (maturity-onset diabetes of the youth) et le diabète gestationnel.
Latest bibliographic data on file with the International Bureau